<DOC>
	<DOCNO>NCT00996892</DOCNO>
	<brief_summary>This open-label , multicenter , Phase Ib dose-escalation study design assess safety , tolerability pharmacokinetics oral dose cobimetinib pictilisib administer combination patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Cobimetinib Combination With Pictilisib Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically cytologically document , locally advanced metastatic solid tumor standard therapy either exist proven ineffective intolerable Evaluable disease disease measurable per Response Evaluation Criteria Solid Tumors ( RECIST ) Life expectancy great equal ( &gt; = ) 12 week Adequate hematologic end organ function Agreement use effective form contraception duration study History prior significant toxicity another mitogenactivated protein kinase ( MEK ) pathway inhibitor require discontinuation treatment History prior significant toxicity another phosphoinositide 3kinase ( PI3K ) pathway inhibitor require discontinuation treatment Allergy hypersensitivity component cobimetinib pictilisib formulation Palliative radiotherapy within 2 week prior first dose study drug treatment Cycle 1 Experimental therapy within 4 week prior first dose study drug treatment Cycle 1 Major surgical procedure significant traumatic injury within 4 week prior first dose study drug treatment Cycle 1 , anticipation need major surgery course study treatment Prior anticancer therapy within 28 day first dose study drug treatment Cycle 1 History diabetes require daily medication , history Grade &gt; = 3 fast hyperglycemia Current severe , uncontrolled systemic disease History clinically significant cardiac pulmonary dysfunction History malabsorption condition would interfere enteral absorption Clinically significant history liver disease ( include cirrhosis ) , current alcohol abuse , current know active infection human immunodeficiency virus ( HIV ) , hepatitis B virus , hepatitis C virus Any condition require anticoagulant , warfarin , heparin , thrombolytic Active autoimmune disease Uncontrolled ascites require weekly large volume paracentesis 3 consecutive week prior enrollment Pregnancy , lactation , breastfeed Known brain metastasis untreated , symptomatic , require therapy control symptoms No history ongoing malignancy would potentially interfere interpretation pharmacodynamic efficacy assay</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GDC0941</keyword>
	<keyword>GDC0973</keyword>
	<keyword>MEK</keyword>
	<keyword>MEK Inhibitor</keyword>
	<keyword>PI3K</keyword>
	<keyword>PI3K Inhibitor</keyword>
	<keyword>PI3 Kinase</keyword>
	<keyword>PI3 Kinase Inhibitor</keyword>
</DOC>